Fathom Therapeutics Raises $47 Million to Accelerate AI-Driven Drug Discovery

# Fathom Therapeutics Raises $47 Million to Accelerate AI-Driven Drug Discovery

The team behind the Anton supercomputer has a new name, a new war chest, and a bet that physics-based simulation -- not pattern matching alone -- will crack the hardest problems in small molecule design.

Fathom Therapeutics, formerly known as Atommap Corp., announced an oversubscribed $47 million Series A financing on April 27, with Sutter Hill Ventures leading the round. Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures also participated. The capital will fund the expansion of Fathom's internal drug discovery programs, scale its lab-in-the-loop capabilities, and grow the team around its core technology: a platform called Microcosmos that simulates protein motion at atomic resolution.

The rebrand from Atommap to Fathom Therapeutics signals the company's shift from pure computational research to an operational drug design outfit with clinical ambitions. And the pedigree behind it is formidable. Fathom's founding team built the Anton supercomputer at D.E. Shaw Research, long considered the gold standard in molecular dynamics simulation, and created the most widely used software for predicting how drugs bind to proteins. Collectively, the leadership team has advanced 19 drugs to the clinic, including seven that earned FDA approval.

At the center of the company's approach is Microcosmos, a platform that Fathom describes as a "world model of drugs in living cells." Where most AI-driven drug discovery companies rely on static protein structures -- essentially frozen snapshots of molecules -- Microcosmos simulates how proteins actually move, flex, and interact in a cellular environment. The platform uses proprietary algorithms that accelerate protein dynamics modeling by 10,000 times compared to conventional methods, without sacrificing accuracy. That speed advantage is critical: it means Fathom can run simulations that would normally take months in a matter of hours, generating the kind of dynamic data that static structure-based approaches miss entirely.

"Current drug discovery efforts are limited by reliance on static structures of isolated proteins," said Huafeng Xu, PhD, Co-Founder and CEO of Fathom Therapeutics. "Microcosmos is a world model of drugs in living cells that surpasses these limitations by translating accurate quantum mechanical calculations to measurable cellular outcomes."

The results so far suggest this is more than theoretical promise. Fathom has an active internal pipeline, multiple discovery partnerships, and has advanced its lead program into animal efficacy studies. In one particularly striking case, the company used Microcosmos to generate novel degraders against a target widely considered "undruggable." Within six weeks, the platform produced potent, highly selective candidates that are now being optimized for clinical advancement -- a timeline that would be exceptional by conventional drug discovery standards.

The $47 million round was oversubscribed, a sign of strong investor conviction in a biotech funding environment that has grown markedly more selective. Keith Loebner, Managing Director at Sutter Hill Ventures, framed the investment in unusually emphatic terms.

"We backed Huafeng because he wanted to rethink how machines understand molecules, combining the best of physics and machine learning to actually move the frontier in computational drug design," Loebner said. "He and the world-class team he's assembled have demonstrated that their approach not only works, but works better than we imagined."

Fathom enters a crowded but rapidly maturing AI drug discovery landscape. Generate Biomedicines held a $425 million IPO in early 2026 focused on AI-driven protein design. Recursion and MIT released Boltz-2, an open-source biomolecular foundation model delivering near physics-level binding affinity predictions at speeds up to 1,000 times faster than traditional free-energy perturbation simulations. Schrodinger continues to combine physics-based simulations with machine learning. And pharma giants are placing bigger bets than ever, exemplified by Lilly's expanded NVIDIA computational lab partnership.

What distinguishes Fathom is its insistence on grounding AI in first-principles physics rather than treating machine learning as a standalone solution. Most AI drug discovery platforms train models on existing experimental data -- an approach that works well for targets and chemical spaces where data is abundant, but struggles with novel biology. Fathom's physics-based simulation generates its own training data from quantum mechanical calculations, potentially giving it an edge on targets where historical data is sparse or nonexistent.

The company also announced two key leadership additions alongside the funding. Mandana Honu, PhD, has joined as Chief Business Officer, and Diala Ezzeddine, PhD, a biotech entrepreneur with over 20 years of experience founding and scaling life science companies, has joined the board of directors. Both hires point toward commercial acceleration and partnership development.

The broader signal from this round is clear. After several years of hype, correction, and consolidation, AI drug discovery investors are gravitating toward companies that can demonstrate not just computational novelty but tangible biological results. Fathom's six-week path from simulation to potent degrader candidates against an undruggable target, its pipeline advancing into animal studies, and the deep domain expertise of its team all fit that pattern. The question now is whether Microcosmos can deliver at scale -- moving from early proof points to a consistent engine for producing clinical candidates across multiple therapeutic areas.

With $47 million in fresh capital and a platform that bridges the gap between quantum mechanics and cellular biology, Fathom Therapeutics is making one of the more scientifically ambitious bets in the current AI drug discovery wave. If the physics holds, the payoff could reshape how the industry thinks about computational drug design.

---

Sources: [PR Newswire](https://www.prnewswire.com/news-releases/fathom-therapeutics-formerly-atommap-raises-47-million-in-oversubscribed-series-a-financing-to-translate-physics-and-ai-enabled-small-molecule-design-into-next-generation-medicines-302754272.html), [Citybiz](https://www.citybiz.co/article/837565/fathom-therapeutics-raises-47-million-series-a-to-advance-physics-and-ai-driven-drug-design-platform/), [FinSMEs](https://www.finsmes.com/2026/04/fathom-therapeutics-raises-47m-in-series-a-funding.html), [TechNews180](https://technews180.com/healthtech-and-medtech/fathom-therapeutics-rebrands-and-raises-47m-series-a/)